MedTrace Logo

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

NCT00212329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-05-13

No results posted yet for this study

Summary

Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

PROCEDURE

T Cell Proliferation and Autoreactivity Assays

PROCEDURE

Cellular Immunoblot Assays

PROCEDURE

Tetramer Studies

PROCEDURE

Cytokine ELISPOT

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Jay E Skyler, MD · Type 1 Diabetes TrialNet Study Chairman

Eligibility

Min Age
8 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Completion
2007-09-30

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212329 on ClinicalTrials.gov